Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 10/20 | 0.51 |
| ▸ | TACR1 | P25103 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | PDE4D | Q08499 | 3/20 | 0.42 |
| ▸ | PDE4A | P27815 | 2/20 | 0.42 |
| ▸ | PDE4B | Q07343 | 2/20 | 0.42 |
| ▸ | PDE4C | Q08493 | 2/20 | 0.42 |
| ▸ | KDM1A | O60341 | 1/20 | 0.41 |
| ▸ | MGLL | Q99685 | 1/20 | 0.41 |
| ▸ | NAMPT | P43490 | 1/20 | 0.41 |
| ▸ | STS | P08842 | 1/20 | 0.40 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25412585 | 0.91 | GPR119 (0.46) | GPR119TACR1MAPTPDE4DPDE4A | |
| SCHEMBL29024545 | 0.89 | GPR119 (0.45) | GPR119TACR1MAPTPDE4DPDE4A | |
| SCHEMBL30490303 | 0.89 | GPR119 (0.54) | GPR119PDE4DPDE4APDE4BPDE4C | |
| SCHEMBL30801945 | 0.87 | GPR119 (0.52) | GPR119PDE4DPDE4APDE4BPDE4C | |
| SCHEMBL23150541 | 0.86 | FFAR4 (0.41) | GPR119MGLLFFAR4 | |
| SCHEMBL1474406 | 0.84 | KDM1A (0.49) | GPR119KDM1AMGLLNAMPT | |
| SCHEMBL30700727 | 0.84 | GPR119 (0.50) | GPR119MAPTPDE4DPDE4APDE4B | |
| SCHEMBL20491222 | 0.82 | ABHD6 (0.58) | GPR119TACR1KDM1AMGLL | |
| SCHEMBL30758634 | 0.82 | ABHD6 (0.58) | GPR119TACR1KDM1AMGLL | |
| SCHEMBL30801985 | 0.81 | GPR119 (0.47) | GPR119PDE4DPDE4APDE4BPDE4C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12577257-B2 | Heterocyclic compounds | HOFFMANN-LA ROCHE INC. (US) | 2026-03-17 | — | — | US | disclosed |
| CN-119301113-A | Novel heterocyclic carbonyl cyclic compounds as MAGL inhibitors | 豪夫迈·罗氏有限公司 | 2025-01-10 | — | — | CN | disclosed |
| WO-2023247670-A1 | NEW HETEROCYCLIC-CARBONYL-CYCLIC COMPOUNDS AS MAGL INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2023-12-28 | — | — | WO | disclosed |
| EP-3883936-B1 | NEW HETEROCYCLIC COMPOUNDS | HOFFMANN LA ROCHE (CH) | 2023-07-12 | — | — | EP | disclosed |
| EP-4034541-A1 | HETEROCYCLIC COMPOUNDS | F. Hoffmann-La Roche AG (CH) | 2022-08-03 | — | — | EP | disclosed |
| CN-114364684-A | Heterocyclic compounds | 豪夫迈·罗氏有限公司 | 2022-04-15 | — | — | CN | disclosed |
| US-20220106328-A1 | HETEROCYCLIC COMPOUNDS | HOFFMANN-LA ROCHE INC. (US) | 2022-04-07 | — | — | US | disclosed |
| US-20210387999-A1 | HETEROCYCLIC COMPOUNDS | HOFFMANN-LA ROCHE INC. (US) | 2021-12-16 | — | — | US | disclosed |
| EP-3883936-A1 | NEW HETEROCYCLIC COMPOUNDS | F. Hoffmann-La Roche AG (CH) | 2021-09-29 | — | — | EP | disclosed |
| US-20210094972-A1 | HETEROCYCLIC COMPOUNDS | HOFFMANN-LA ROCHE INC. (US) | 2021-04-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210387999-A1 | HETEROCYCLIC COMPOUNDS | CYP1B1, CYP4B1, CYP4X1 | GPR119 2884/4885TACR1 2095/4885MAPT 3708/4885 |
| US-20220106328-A1 | HETEROCYCLIC COMPOUNDS | CYP1B1, CYP4B1, CYP1A1 | GPR119 4041/4885TACR1 2957/4885MAPT 2573/4885 |
| US-20210094972-A1 | HETEROCYCLIC COMPOUNDS | CYP1B1, CYP4B1, CYP1A1 | GPR119 4041/4885TACR1 2957/4885MAPT 2573/4885 |
| US-12577257-B2 | Heterocyclic compounds | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, CBR1, CBR3 | GPR119 2693/4885TACR1 1082/4885MAPT 3680/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.